@AliceIndini profile picture
Alice Indini @AliceIndini
Joined December 2021
  • Tweets 16
  • Following 90
  • Followers 73
Photos and videos
What is the real benefit of adjuvant therapy in stage II and III melanoma? A group of experts critically reviewed the results so far reported. A must read article to guide therapeutic choices in a debated setting! #IAmPractisingOncologist #melanoma ejcancer.com/article/S0959-8…

Adjuvant therapy for stage II melanoma: the need for further studies

Immunotherapy with checkpoint inhibitors has revolutionised the outcomes for melanoma patients. In the metastatic setting, patients treated with nivolumab and ipilimumab have an expected 5-year...

ejcancer.com
4
11
1,779
Alice Indini retweeted
Benedetta Pellegrino@bpellegrino89
13 May 2023
Great job, #Iampractisingoncologist! We r the @esmo_eur_oncology commitee involved in feeling the gap between research and daily clinical practice. If you have a full 8-hours clinic and look4a way to be updated on what’s going on in the oncology field, welcome on board!
3
4
20
1,690
Alice Indini retweeted
ESMO - Eur. Oncology
@myESMO
28 Dec 2022
Alexios Matikas, OncologyPRO Working Group Member & ESMO #YoungOncologist Committee Member, on why OncologyPRO is an essential tool to help oncologists in their #dailypractice, thanks to its accessibility, ease of use, and content depth. ow.ly/pmwU50M9esW #oncology
1:39
3
7
2,991
Alice Indini retweeted
Alberto Cunquero@alcunto
6 Oct 2022
Great job from the Practising Oncologist Working Group! Very useful!!!!
ESMO - Eur. Oncology
@myESMO
6 Oct 2022
Recently updated 📢 All 15 ESMO Checklists: hands-on self-assessment tools to help you check essential steps recommended in ESMO Guidelines have been taken in your daily practice ow.ly/5Uu750L3312 @brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD
1
5
Alice Indini retweeted
ESMO - Eur. Oncology
@myESMO
19 Sep 2022
Calling all practising oncologists 📢 Take the ESMO Practising Oncologists Working Group survey so we can better understand your practice needs & opinions on current products. ow.ly/FS3650KMUi7 @brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD
11
18
Alice Indini retweeted
Mario Mandala@MandalaMario
26 Jun 2022
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. pubmed.ncbi.nlm.nih.gov/3575…

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges -...

Immune checkpoint inhibitors (ICIs) have demonstrated impressive antitumor activity in patients with advanced and early stage melanoma, thus improving long-term survival outcomes. However, most...

pubmed.ncbi.nlm.nih.gov
2
9
Alice Indini retweeted
Florentia Dimitriou, MD PhD PD@FDimitriouMD
18 Jun 2022
Our study on #mucosal #melanoma is now online in @Annals_Oncology - Although retrospective, this study represents the largest report to date analyzing the efficacy of ICIs in this rare cancer that carries a poor prognosis. Here are some key points:
Annals of Oncology@Annals_Oncology
17 Jun 2022
Mucosal melanoma, representing 2% of melanomas, has a distinct biology & carries a poor prognosis. In this cohort of 545 patients published in Annals of Oncology, @FDimitriouMD @ProfGLongMIA and coll. studied the efficacy of immune checkpoint inhibitors annalsofoncology.org/article…
1
8
18
Alice Indini retweeted
ESMO - Eur. Oncology
@myESMO
20 Mar 2022
Soft Tissue #Sarcomas Webinar ⏰ 29/3, 18:30 CEST Registration open for this live discussion of a real-world case. Live viewers: certificate of attendance & 1 ESMO-MORA point Full info 🔗 ow.ly/YIT950ImoNY @AliceIndini @SilviaStacchia @pawel_sobczuk @jeanyvesblay #scmsm
7
17
Alice Indini retweeted
ESMO - Eur. Oncology
@myESMO
9 Feb 2022
#ESMOPreceptorship on Molecular #CancerBiology for Practising Oncologists & #Cancer Treatment De-escalation 2022: Multidisciplinary management, standards of care & future perspectives ow.ly/pgJv50HQFsZ @BennounaJaafar @brasiuniene @PietDirix @G_LipositsMD @LazarPo31787807
9
12
Alice Indini retweeted
Cancer Discovery@CD_AACR
12 Jan 2022
Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. bit.ly/3GkSqZK @Ludwig_Cancer
20
784
1,776
Alice Indini retweeted
Hussein Tawbi, MD, PhD
@HTawbi_MDPhD
6 Jan 2022
On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.1056/NE…

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma | NEJM

Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3–blocking a...

nejm.org
23
99
405
Alice Indini retweeted
Meredith GTrinidad, MD@DrMeredithGT
30 Dec 2021
👉 Check out the @myESMO Practicing Oncologists Working Group's new series of Spotlight presentations featuring highlights from #ESMO21 oncologypro.esmo.org/meeting…
5
8
Alice Indini retweeted
Mario Mandala@MandalaMario
24 Dec 2021
Mucosal melanomas: molecular profile and therapy. What physicians need to know!!
3
9
Alice Indini retweeted
Journal for ImmunoTherapy of Cancer
@jitcancer
13 Dec 2021
New #JITC article: Combinatorial immunotherapy induces tumor-infiltrating CD8 T cells with distinct functional, migratory, and stem-like properties bit.ly/3pW3yFk @SripadRam
3
3
Do not miss! clustersrl.it/res-wfsc?fbcli…
Load more